The development of tau-targeting PROTACs benefited greatly from advances in the field of tauopathy biomarkers and diagnostics that spurred the development of several PET tracers [99] that bind preferentially to misfolded and amyloid tau species in living patient brains [100]. The gene discussed is MAPT; the disease is tauopathy.